Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study

By afschroeder • April 18, 2026

Mysler E, Sidiropoulos PI, Balanescu A, Detert J, Xavier RM, Charles-Schoeman C, Bessette L, Crowley A, Kaneko Y, Zhang Z, Nagy O, Liu Y, Ren J, Romero AB, Suboticki JL, DeMasi R, Meerwein S, Fleischmann R; SELECT-SWITCH Study Investigators. Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study. Ann Rheum Dis. 2026 Apr 15:S0003-4967(26)00198-6. doi: 10.1016/j.ard.2026.03.013. Epub ahead of print. PMID: 41991443.

Tags: Publications, Rheumatology

Validating ICD code case definitions for condition case ascertainment in multimorbidity measurement: a retrospective chart review

Kang AJ, Tseng CH, Wei MY. Validating ICD code case definitions for condition case ascertainment in multimorbidity measurement: a retrospective chart review. J Gerontol A[...]

Colocalization of eQTLs With Type 2 Diabetes and Glycemic Traits Using Whole-Genome Sequences in Diverse Populations From the NHLBI Trans-Omics in Precision Medicine (TOPMed) Program

Wang N, DiCorpo DA, Zhang Y, Kleinbrink E, Arnett DK, Barnard J, Blangero J, Bowden DW, Carson AP, Chen YI, Chung MK, Curran JE, Darbar[...]

Defining Diagnostic Excellence and Missed Diagnostic Opportunity for the Emergency Department Setting

Berdahl CT, Schiff GD, Venkatesh AK, Seferian EG, Torbati SS, Ptacek MP, Carrascoza-Bolanos J, Qureshi N, Nuckols TK; Multidisciplinary ED Diagnostic Excellence Panel. Defining Diagnostic[...]